Phase 3 N=17 A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud's Phenomenon
Raynaud · Scleroderma
Primary: The Time to Recover 50% of Fall in the Baseline Skin Temperature. — 7.5; 8.2; 7.9 minutes
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=151 Systemic Lupus Erythematous and Heart Conduction Disorders
Lupus Erythematosus, Systemic · Atrioventricular Block · Sudden Death
Primary: Presence of Conduction Disorders in Patients With SLE Regarding to Its Serologic Profile — 89.22; 91.41; 145.68; 146.72 msec
Phase 2 N=34 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 2)
Raynaud Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -14.32; -15.09 Number of RP attacks per week — p=0.8498
Phase 2 N=243 PF-00489791 For The Treatment Of Raynaud's
Raynaud's Disease · Peripheral Vascular Disease
Primary: Change From Baseline in Mean Raynaud's Condition Score (RCS) at Week 4 — 3.04; 2.90; 2.98; 3.14 units on a scale — p=0.6513
Phase 2 N=69 A Study to Investigate Safety of GS-248 and Efficacy on Raynauds' Phenomenon in Systemic Sclerosis
Systemic Sclerosis
Primary: Mean Change From Baseline to Week 4 in the Number of Raynaud Attacks Per Week. — -3.41; -4.22 number of attacks — p=<0.05
N/A N=10 Tadalafil for the Treatment of Raynaud's
Raynaud
Primary: Number of Raynaud's Phenomenon Attacks Per Day — 2.4; 1.1; 2.0; 2.3 Raynaud's attacks per day
Phase 3 N=196 Intravenous Iloprost in Subjects With Symptomatic Raynaud's Phenomenon Secondary to Systemic Sclerosis (Phase 3)
Raynaud's Phenomenon Secondary to Systemic Sclerosis
Primary: Change in Frequency of Symptomatic RP Attacks — -11.47; -12.73 Number of RP attacks per week — p=0.4210
Phase 2 N=57 Rituximab for Treatment of Systemic Sclerosis-Associated Pulmonary Arterial Hypertension (SSc-PAH)
Systemic Sclerosis-Associated PAH
Primary: Change From Baseline in Distance Walked During a Six Minute Walk Test — 23.6; 0.5 Meters — p=0.12
N/A N=20 Efficacy of Ambrisentan in Limited Scleroderma Patients in Improving Blood Flow to Hands or Feet
Ischemia
Primary: Digital Micro-vascular Flow — .11; .18; -.01; -.06 perfusion unit
Phase 3 N=29 Efficacy Study of PDE-5 Inhibitor and Calcium Channel Inhibitor for the Treatment of Secondary Raynaud Phenomenon
Raynaud Phenomenon
Primary: RP Attacks Per Day — -0.5; -0.5 attacks per day
Phase 2 N=19 IL1-TRAP, Rilonacept, in Systemic Sclerosis
Scleroderma · Systemic Sclerosis · Diffuse Scleroderma
Primary: Change in 2- Gene Biomarker — -2.67; 0.42 2- gene biomarkers score
Phase 2 N=12 Cold Challenge With C21 in RP
Raynaud Phenomenon · Systemic Sclerosis
Primary: Area Under the Curve for Rewarming of Each Finger After Cold Challenge (AUC) as Measured by Thermography — 19558.43; 20045.96 C*sec — p==0.3801
Phase 2 N=24 Atorvastatin for Microvascular Endothelial Function and Raynaud in Early Diffuse Scleroderma
Scleroderma
Primary: Proportion of Patients Improving Their EndoPAT Reactive Hyperemia Index (RHI) at the End-of-study (16 Weeks) — 6; 4 Participants
Phase 2 N=65 Efficacy and Safety of Vascana® in Subjects With Secondary Raynaud's Phenomenon
Raynaud's Phenomenon Secondary to Connective Tissue Disease
Primary: Raynaud's Symptom Severity (Change From Baseline) — -20.19; -18.63 score on a scale
Phase 2 N=12 Systemic Sclerosis (SSc) Vasculopathy: Improved Clinical Monitoring and Treatment
Rheumatologic Disease
Primary: Flow Mediated Dilatation (FMD)-Diameter of Artery — 3.79; 3.78 mm
Phase 2 N=17 Riociguat in Scleroderma Associated Digital Ulcers
Scleroderma · Digital Ulcers
Primary: Change From Baseline to End of Double-blind Treatment (Week 16) in Digital Ulcer Net Burden — -1.22; -0.98 ulcers — p=0.70
Phase 3 N=158 Scleroderma Lung Disease
Lung Diseases · Pulmonary Fibrosis · Systemic Scleroderma
Primary: Forced Vital Capacity — 66.6; 65.6 % of predicted
Phase 2 N=97 Effectiveness and Safety of SAR156597 in Treating Diffuse Systemic Sclerosis
Systemic Sclerosis
Primary: Change From Baseline in Modified Rodnan Skin Score to Week 24 — -2.45; -4.76 score on a scale — p=0.0291
N/A N=10 Botulinum Toxin in the Treatment of Raynaud's
Raynaud's Syndrome
Primary: Mean Digital Temperature Difference From Baseline — 1.30 Celsius
N/A N=15 Study of Ambrisentan With Antifibrotic Agent Combination Therapy in Diffuse Systemic Sclerosis
Systemic Sclerosis · Scleroderma
Primary: The Benefit That an Antifibrotic Agent and Ambrisentan Combination Have on the Cutaneous Involvement of Patients With Early Diffuse Systemic Sclerosis by Utilizing the…
Phase 2 N=142 Comparison of Therapeutic Regimens for Scleroderma Interstitial Lung Disease (The Scleroderma Lung Study II)
Scleroderma · Interstitial Lung Disease
Primary: Forced Vital Capacity (FVC), as a Percent of the Age, Height, Gender, and Ethnicity Adjusted Predicted Value — 66.52; 66.52; 66.22; 67.03 FVC %-pred — p=0.24
Phase 2 N=10 A Study to Evaluate the Safety and Efficacy of Abatacept in Patients With Diffuse Systemic Sclerosis (Scleroderma)
Scleroderma, Diffuse · Scleroderma, Systemic
Primary: Change in Modified Rodnan Skin Score — -8.6; -2.3 MRSS score
Phase 2 N=19 Cyclophosphamide and rATG With Hematopoietic Stem Cell Support in Systemic Scleroderma
SYSTEMIC SCLERODERMA
Primary: Time to Treatment Failure — 0; 8 participants
Phase 2 N=121 Efficacy and Safety of Riociguat in Patients With Systemic Sclerosis
Scleroderma, Systemic
Primary: Change From Baseline in Modified Rodnan Skin Score (mRSS) to Week 52 — -2.088; -0.769 score on a scale — p=0.0815
Phase 3 N=6 High Dose Cyclophosphamide for Treatment of Scleroderma
Scleroderma
Primary: Improvement in the Modified Rodnan Skin Score. — 46.75 percent improvement from baseline
Phase 2 N=41 Efficacy and Tolerability of Ginkgo Biloba Extract in Patients With Raynaud´s Phenomenon
Raynaud Disease
Primary: Frequency of Vasospastic Attacks — 2.4; 2.0 attacks per day
N/A N=26 Beet the Cold: The Effect of Inorganic Nitrate Supplementation in Individuals With Raynaud's Phenomenon
Raynaud Phenomenon
Primary: Peripheral Blood Flow — 3.7; 3.7; 4.1; 3.7 flux.mmHg-1
Phase 3 N=10 Rituximab in Rheumatoid Arthritis Lung Disease
Rheumatoid Arthritis · Interstitial Pneumonia
Primary: Change in Diffusion Capacity for Carbon Monoxide (DLco) From Baseline to 48 Weeks — 4; 2; 1 participants
Phase 3 N=80 Efficacy of Botulinum Toxin In Scleroderma-Associated Raynaud's Syndrome
Scleroderma · Raynaud's Syndrome
Primary: Change in Digital Blood Flow From Pre- to Post-injection. — -36.19; -6.10 Blood flow, measured in LDI flux units,
N/A N=27 Hands on - a Hand Care Guide in Systemic Sclerosis
Scleroderma
Primary: Cochin Hand Functional Scale — 19.24 units on a scale